0001209191-20-043562.txt : 20200723 0001209191-20-043562.hdr.sgml : 20200723 20200723212120 ACCESSION NUMBER: 0001209191-20-043562 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200723 FILED AS OF DATE: 20200723 DATE AS OF CHANGE: 20200723 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Florence Anthony A. Jr. CENTRAL INDEX KEY: 0001559827 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 201044889 MAIL ADDRESS: STREET 1: 5425 WISCONSIN AVENUE, SUITE 800 CITY: CHEVY CHASE STATE: MD ZIP: 20815 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-07-23 0 0001693011 Inozyme Pharma, Inc. INZY 0001559827 Florence Anthony A. Jr. 5425 WISCONSIN AVENUE, SUITE 800 CHEVY CHASE MD 20815 0 0 1 0 Series A Preferred Stock Common Stock 2000533 I See Note 2 Series A-2 Preferred Stock Common Stock 187156 I See Note 2 The Series A Preferred Stock is convertible into Common Stock on a 7.473-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's selection or upon closing of the initial public offering of the Issuer's Common Stock. The shares have no expiration date. The Reporting Person is a manager of NEA 15 GP, LLC, which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L.P. ("NEA 15"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 15 in which the Reporting Person has no pecuniary interest. The Series A-2 Preferred Stock is convertible into Common Stock on a 7.473-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's selection or upon closing of the initial public offering of the Issuer's Common Stock. The shares have no expiration date. /s/ Sasha Keough, attorney-in-fact 2020-07-23